Clearance of erythrocyte allo-antibodies using Rituximab.
Gryn
J
J
Zeigler
Z R
ZR
Shadduck
R K
RK
Thomas
C
C
D000373:Agglutinins / Q000096:biosynthesis / Q000097:blood*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D016175:B-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D001789:Blood Group Antigens / Q000276:immunology*; D003450:Cryoglobulins; D004910:Erythrocyte Membrane / Q000276:immunology*; D017707:Erythrocyte Transfusion / Q000009:adverse effects; D017809:Fatal Outcome; D005312:Fetal Blood / Q000166:cytology; D006471:Gastrointestinal Hemorrhage / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use; D007518:Isoantibodies / Q000096:biosynthesis / Q000097:blood*; D007626:Kell Blood-Group System / Q000276:immunology; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000276:immunology / Q000628:therapy*; D000069283:Rituximab; D018746:Systemic Inflammatory Response Syndrome / Q000150:complications
D000373:Agglutinins; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001789:Blood Group Antigens; D003450:Cryoglobulins; D007518:Isoantibodies; D007626:Kell Blood-Group System; C029443:cold agglutinins; D000069283:Rituximab; D007372:Interferons